文献速递精神分裂症与精神病性障碍

精神分裂症患者抗精神病药治疗反应的全基因组关联研究:五个新位点

Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
PubMed 文献 · Lancet Psychiatry · 2018-03-01

该研究在中国精神分裂症患者中开展全基因组关联研究,发现队列2413例、验证队列1379例,鉴定出五个与抗精神病药治疗反应全基因组显著相关的新位点,并发现部分药物特异性相关位点。

要点

  • 五个新位点与抗精神病药 general 治疗反应全基因组显著相关。
  • MEGF10、SLC1A1、PCDH7 位点在验证队列中得到重复。
  • CACNA1C、SLC1A1、CNTN4 位点分别与奥氮平、利培酮、阿立哌唑反应相关。

核心结论

  • 发现五个与精神分裂症患者抗精神病药治疗反应全基因组显著相关的新位点,涉及突触功能、神经递质受体及精神分裂症风险基因。

研究设计与样本

  • 发现队列为来自中国32家精神病医院的患者,随机分配至六种抗精神病药治疗6周。
  • 验证队列为来自5家协作医院的患者,接受奥氮平、利培酮或阿立哌唑治疗8周。
  • 发现队列2413例,验证队列1379例,以PANSS百分比变化量化治疗反应。

临床怎么用

  • 这些位点有望作为生物标志物,未来指导精神分裂症患者抗精神病药的个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. METHODS: The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p<1 × 10-5) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. FINDINGS: The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1·37 × 10-8], rs1471786 in SLC1A1 [p=1·77 × 10-8], and rs9291547 in PCDH7 [p=4·48 × 10-8]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p<0·05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1·40 × 10-9], rs1471786 in SLC1A1 [p=2·33 × 10-9], rs9291547 in PCDH7 [p=3·24 × 10-9], rs12711680 in CNTNAP5 [p=2·12 × 10-8], and rs6444970 in TNIK [p=4·85 × 10-8]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1·10 × 10-8), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4·40 × 10-8), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2·58 × 10-8). INTERPRETATION: We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia. FUNDING: National Key Technology R&D Program of China, National Natural Science Foundation of China.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yu H, Yan H, Wang L, et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry. 2018. PMID: 29503163. doi:10.1016/S2215-0366(18)30049-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。